FDA Closes 2013 With Flurry Of Citations For Misleading Rx Promotions
This article was originally published in The Pink Sheet Daily
Office of Prescription Drug Promotion issues 23 letters in 2013, five less than the previous year.
You may also be interested in...
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
Agency’s recent approval of Enhertu, which has better response rate, sways some panel members to vote against Spectrum’s NSCLC drug. FDA’s Pazdur compares poziotinib’s dosing uncertainty to ‘building a house on quicksand.’
Leaders of FDA’s oncology center say sponsors could initiate a single randomized trial prior to receiving accelerated approval or conduct a single-group AA study concurrently with a randomized trial. FDA and sponsor could agree in advance on criteria for approval and withdrawal.